Type 2 Diabetes Mellitus MeSH:D003924KIDPERNCT07256613
Non-surgical Periodontal Therapy and Kidney Outcomes in Type 2 Diabetes Mellitus
A study testing scaling and root planning in people with Type 2 Diabetes Mellitus MeSH:D003924 and Periodontitis MeSH:D010518, run by Dow University of Health Sciences at 1 site in Pakistan.
Trial summary
Brief Summary (Lay Description) This research study is being conducted to understand whether treating gum disease (periodontitis) can help improve kidney health in patients who have type-2 diabetes mellitus (T2DM). Both diabetes and gum disease are common long-term conditions that often occur together. Read more about this study
- Who is it for?
- Ages 30 to 65 years
- Conditions the study is for
- Type 2 Diabetes Mellitus MeSH:D003924, Periodontitis MeSH:D010518, Diabetic Nephropathies MeSH:D003928
- What is being tested?
- scaling and root planning
- Type of treatment
- Pill or oral medicine, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 46 participants
- Where
- 1 sitePakistan
- Study dates
- 15 May 2025to 19 Aug 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults between 30 and 65 years of age
- Men and women previously diagnosed with type 2 diabetes mellitus for at least one year
- Participants with uncontrolled diabetes, defined as HbA1c ≥ 7%
- Presence of moderate to severe gum disease, Stage II or Stage III periodontitis, as determined by dental examination
- Estimated glomerular filtration rate (eGFR) of 60 mL/min/1.73 m² or higher
- Willing and able to provide written informed consent
Who cannot join
- Critically ill individuals or those unable to communicate effectively
- Pregnant or breastfeeding women
- Women currently using hormone replacement therapy or oral contraceptives within the past six months
- Individuals taking steroidal drugs, nonsteroidal anti-inflammatory drugs (NSAIDs), or other anti-inflammatory medications within the past three months, except low-dose aspirin up to 75 mg daily
- Participants with a recent history of major blood loss, trauma, or gastrointestinal bleeding
- Use of antibiotics within the last month
Show all 10Show fewer
- History of fever or vomiting lasting more than one week within the last month
- Regular tobacco or alcohol users
- Individuals with any other chronic disease or condition that could interfere with study outcomes
- Individuals unwilling or unable to comply with study procedures or follow-up visits
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Outcomes of Non-surgical Periodontal Therapy on Urea and Creatinine Levels in Type-2 Diabetes Mellitus Patients
Brief Summary (Lay Description)
This research study is being conducted to understand whether treating gum disease (periodontitis) can help improve kidney health in patients who have type-2 diabetes mellitus (T2DM). Both diabetes and gum disease are common long-term conditions that often occur together. People with uncontrolled diabetes are at risk of developing kidney problems due to damage in the small blood vessels of the kidneys - a condition known as diabetic nephropathy.
Read more
Scientific evidence has already shown that treating gum disease can help improve blood sugar control in diabetic patients. However, it is still unclear whether gum treatment can also help reduce the risk or severity of kidney-related complications. This study aims to find out if non-surgical periodontal therapy (NSPT), which includes scaling and root planing (deep dental cleaning), has any effect on blood markers of kidney function - specifically urea, creatinine, and estimated glomerular filtration rate (eGFR) - in patients with uncontrolled type-2 diabetes.
The study will be conducted as a randomized controlled trial involving 46 patients with uncontrolled T2DM (HbA1c ≥ 7%) who also have moderate to severe gum disease. Participants will be divided randomly into two groups:
Test Group: Will receive full-mouth non-surgical periodontal therapy (scaling and root planing) and oral hygiene instructions.
Control Group: Will receive oral hygiene instructions only and will get the same gum treatment later (after 90 days, as delayed therapy).
All participants will have their gum health examined, and blood tests will be done at the start and again after 90 days to measure urea, creatinine, and eGFR levels. These tests help determine how well the kidneys are working. The changes in these values before and after gum treatment will show whether improving oral health has any beneficial impact on kidney function in diabetics.
The study is expected to take one year and will be conducted at Dow University of Health Sciences, Karachi. All participants will receive standard dental and laboratory assessments at no cost. The results may help improve future strategies for managing diabetic patients by integrating oral health care with medical care.
Purpose:
To determine whether treating gum disease (through non-surgical periodontal therapy) can improve kidney function markers - urea, creatinine, and eGFR - in patients with uncontrolled type-2 diabetes mellitus.
Question being answered:
Does non-surgical periodontal therapy have a positive effect on kidney function in uncontrolled type-2 diabetic patients by reducing urea and creatinine levels and improving eGFR?
Read the detailed description
Detailed Description Background and Rationale
Periodontitis and type 2 diabetes mellitus (T2DM) are both chronic, non-communicable diseases with a well-established bidirectional relationship. Individuals with poorly controlled diabetes are at higher risk of developing periodontal inflammation, while untreated periodontitis may contribute to poor glycemic control through systemic inflammation. Among the microvascular complications of diabetes, nephropathy remains a major cause of morbidity and mortality. It is characterized by glomerular damage, resulting in elevated serum creatinine (SCr) and urea levels, and a reduced glomerular filtration rate (GFR).
Although several studies have shown that periodontal therapy can improve glycemic control, there is limited evidence regarding its effects on renal function in diabetic patients. The systemic inflammatory burden caused by chronic periodontitis may exacerbate kidney dysfunction, as inflammatory mediators such as TNF-α, IL-1β, and prostaglandin E2 circulate systemically and contribute to endothelial damage. This study aims to evaluate whether non-surgical periodontal therapy (NSPT), by reducing periodontal inflammation and bacterial load, can positively influence renal biomarkers in patients with uncontrolled type 2 diabetes mellitus.
The study will provide preliminary interventional data on the potential of periodontal therapy as an adjunctive measure in reducing systemic inflammatory load and possibly delaying microvascular complications, such as diabetic nephropathy. This is particularly relevant in the Pakistani population, where both T2DM and periodontitis have high prevalence, yet local interventional evidence remains scarce.
Study Design and Setting
This is a parallel-arm, single-blinded randomized controlled clinical trial designed to evaluate the effect of NSPT on renal function markers in uncontrolled T2DM patients with moderate to severe periodontitis. The study will be conducted at two sites under Dow University of Health Sciences (DUHS), Karachi:
National Institute of Diabetes and Endocrinology (NIDE) - patient screening and medical evaluation.
Dr. Ishrat-ul-Ebad Khan Institute of Oral Health Sciences (DIKIOHS) - periodontal examination and intervention.
The total duration of the study is projected to be 12 months, including patient recruitment, intervention, 3-month follow-up, data analysis, and report preparation.
Sample Size and Allocation
Based on previous studies assessing serum creatinine differences between periodontitis and non-periodontitis groups, a sample size of 23 participants per arm (n=46 total) has been calculated, accounting for 20% attrition. Participants will be randomly assigned to one of two groups using computer-generated random numbers and allocation concealment via Serially Numbered Opaque Sealed Envelopes (SNOSE).
Test Group: Non-surgical periodontal therapy (scaling and root planing) + standardized oral hygiene instructions (OHI).
Control Group: OHI only; scaling and root planing provided after study completion as delayed therapy (DT).
The principal investigator will remain blinded to the intervention assignment during data collection and analysis.
Intervention Details
- Non-Surgical Periodontal Therapy (NSPT) The NSPT intervention includes full-mouth ultrasonic scaling followed by manual root planing using Gracey curettes. This will be performed in a single session by trained and calibrated dental hygienists under supervision. The procedure aims to remove supra- and sub-gingival plaque and calculus, thereby eliminating bacterial niches contributing to inflammation.
- Oral Hygiene Instructions (OHI) All participants will receive standardized instructions based on the Modified Stillman's brushing technique using a soft-bristle toothbrush and fluoridated toothpaste twice daily. Each participant will receive an identical oral hygiene kit to ensure standardization. Compliance will be monitored through self-maintained daily practice sheets reviewed at follow-up visits.
- Delayed Therapy (DT)
Participants in the control arm will receive the same NSPT procedure after completion of the 90-day follow-up period to ensure ethical equivalence.
Clinical and Laboratory Assessments Baseline Examination
At recruitment, each participant will undergo:
Full-mouth periodontal charting (six sites per tooth) for probing depth (PPD), clinical attachment loss (CAL), and bleeding on probing (BOP).
Collection of demographic, medical, and lifestyle data via structured questionnaire.
Blood sampling for baseline measurement of:
Serum creatinine (SCr)
Blood urea nitrogen (BUN)
Glycated hemoglobin (HbA1c)
Estimated glomerular filtration rate (eGFR), calculated using the Modification of Diet in Renal Disease (MDRD) formula.
Follow-Up Examination
At 90 days post-intervention, all parameters will be re-evaluated to assess intra- and inter-group changes in renal and periodontal health indices.
Blood samples will be collected under aseptic conditions by trained personnel and analyzed by the Dow Diagnostic Laboratory using standardized procedures. Serum separation will be done by centrifugation; assays will follow clinical laboratory reference ranges:
SCr normal range: 0.6-1.5 mg/dL
BUN normal range: 30-40 mg/dL
Normal eGFR cutoff: ≥60 mL/min/1.73 m²
Calibration and Quality Control
All periodontal examinations will be performed by the principal investigator (PI), trained and calibrated against a gold standard examiner (the supervisor). Inter- and intra-examiner reliability will be tested before trial initiation using kappa statistics and intra-class correlation coefficients. The two dental hygienists performing the interventions will undergo calibration sessions to standardize SRP procedures. Random 10% re-evaluation of data will be done to ensure consistency.
Data Management and Statistical Analysis
All data will be anonymized using unique participant identifiers. Data entry will be performed using IBM SPSS version 26.0.
Continuous variables will be expressed as mean ± standard deviation, and categorical variables as frequencies and percentages.
Statistical analyses will include:
Wilcoxon signed-rank test: for within-group comparisons (baseline vs. 90-day values).
Mann-Whitney U test: for between-group comparisons.
Correlation analyses: between periodontal parameters (PPD, CAL, BOP) and renal markers (SCr, BUN, eGFR).
Significance level: p ≤ 0.05. Both per-protocol (PPA) and intention-to-treat (ITT) analyses will be performed to ensure robustness of findings.
Ethical Considerations
The study protocol has been reviewed and approved by the Institutional Review Board (IRB) of Dow University of Health Sciences. Written informed consent will be obtained from all participants prior to enrollment, with separate consent forms in English and Urdu to ensure understanding.
Participation is voluntary, and subjects may withdraw at any stage without penalty. All laboratory and dental procedures will be conducted free of cost. Participants in the control group will receive their complete periodontal therapy after the trial. Data confidentiality will be maintained through de-identification and restricted access.
Potential risks include mild discomfort during blood sampling and transient tooth sensitivity following SRP, both of which are minor and self-limiting. No major adverse effects are anticipated. Participants will have access to dental and medical support throughout the study period.
Expected Outcomes
The study anticipates a measurable improvement in renal function biomarkers (reduction in SCr and BUN levels, and improvement in eGFR) among the NSPT group compared to controls after 90 days. This would support the hypothesis that periodontal inflammation contributes to systemic inflammatory load affecting renal physiology.
Findings will help strengthen the understanding of oral-systemic health connections and may encourage multidisciplinary management of diabetic patients involving both dental and medical professionals.
Scientific Significance and Future Implications
This trial will be one of the first interventional studies from Pakistan evaluating the impact of non-surgical periodontal therapy on renal function in uncontrolled diabetics. The results could:
Provide evidence to include periodontal screening as part of diabetes management protocols.
Support collaborative programs between diabetology and dental departments for early detection and management of oral infections.
Encourage larger multicentric clinical trials exploring the long-term effects of periodontal therapy on renal and systemic outcomes in diabetic populations.
The study's integration of oral health and systemic disease management aligns with global efforts to promote interdisciplinary healthcare and may contribute to policy-level recommendations for diabetic patient care.
- Conditions
- Type 2 Diabetes Mellitus MeSH:D003924, Periodontitis MeSH:D010518, Diabetic Nephropathies MeSH:D003928
- Being tested
- scaling and root planning
- Keywords
- Type 2 Diabetes Mellitus, Uncontrolled Type 2 Diabetes, Diabetes-related nephropathy, Chronic kidney disease (CKD), Diabetic nephropathy, periodontitis, non surgical periodontal therapy, scaling, root palnning, serum creatinine, blood urea nitrogen, BUN, eGFR, MDRD GFR euation, oral hygiene instruction(OHI), Randomised control trial
- Medical subject headings
- Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic, Diabetic Nephropathies, Periodontitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
scaling and root planningProcedure or surgery
Intervention 1: Scaling and Root Planing (SRP) + Oral Hygiene Instructions (OHI)
Intervention Description:
Participants assigned to the intervention arm will receive full-mouth non-surgical periodontal therapy consisting of scaling and root planning (SRP). Ultrasonic scalers will be used to remove supragingival plaque and calculus, followed by hand instruments (curettes and scalers) for subgingival debridement and root planing. The procedure is performed in a single session by trained and calibrated dental hygienists. Participants will also receive standardized oral hygiene instructions (OHI), including demonstration of the Modified Stillman's toothbrushing technique using a soft-bristle toothbrush and fluoridated toothpaste twice daily. Each participant will be provided with an oral hygiene kit to ensure consistency. Postoperative care includes warm saline rinses for three days. No further periodontal treatment will be given during the 90-day follow-up period.
| Study group | Role | What they receive |
|---|---|---|
| Non-Surgical Periodontal Therapy (Scaling and Root Planing + Oral Hygiene Instructions) | Experimental | Participants in this arm will receive full-mouth non-surgical periodontal therapy, including ultrasonic scaling and manual root planing in a single session performed by trained dental hygienists. This treatment aims to remove supra- and subgingival plaque and calculus to reduce periodontal inflammation. Standardized oral hygiene instructions will also be provided, including demonstration of the Modified Stillman's brushing technique using a soft toothbrush and fluoridated toothpaste twice daily. Participants will be monitored for 90 days to assess changes in renal biomarkers (serum creatinine, blood urea nitrogen, and eGFR) Receives: Procedure: scaling and root planning |
| Control - Oral Hygiene Instructions with Delayed Periodontal Therapy | Active comparator | Participants in the control arm will receive only standardized oral hygiene instructions at baseline and will not undergo scaling and root planing during the 90-day study period. After completion of follow-up assessments, they will receive the same periodontal therapy as the intervention group (delayed therapy) to ensure ethical equivalence Receives: Procedure: scaling and root planning |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from Baseline in Serum Creatinine, Blood Urea Nitrogen, and Estimated Glomerular Filtration Rate (eGFR) at 90 Days After Non-Surgical Periodontal Therapy
The primary outcome will be evaluated by measuring changes in renal function biomarkers, including serum creatinine (mg/dL), blood urea nitrogen (BUN, mg/dL), and estimated glomerular filtration rate (eGFR, mL/min/1.73 m²). These parameters will be assessed at baseline and 90 days post-intervention to determine within- and between-group differences. Serum creatinine and BUN will be analyzed using standard automated laboratory methods, and eGFR will be calculated using the Modification of Diet in Renal Disease (MDRD) equation. A reduction in serum creatinine and BUN levels and an increase in eGFR will indicate improvement in renal function. Data will be statistically analyzed using Wilcoxon signed-rank and Mann-Whitney U tests with a significance threshold of p ≤ 0.05
Measured: Baseline and 90 days after completion of non-surgical periodontal therapy
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Dec 2025
- Study start15 May 2025
- Primary completion15 May 2026
- Study completion19 Aug 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Type 2 Diabetes Mellitus MeSH:D003924Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Parallel Assignment - Participants are randomly assigned to one of two groups: an intervention group receiving non-surgical periodontal therapy and a control group receiving delayed therapy after the study period.
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 46 participants (actual)
Sponsor and investigators
- Lead sponsor
- Dow University of Health Sciences
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dr. Muhammad Ather Khan, Dow University of Health Sciences
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07256613
- Sponsor's protocol ID
- 3642/DUHS/Approval/2024/311
- Acronym
- KIDPER
- Status last verified
- Aug 2026
- First submitted
- 20 Nov 2025
- Last updated
- 24 Aug 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 24 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Outcomes of Non-surgical Periodontal Therapy on Urea and Creatinine Levels in Type-2 Diabetes Mellitus Patients
- ClinicalTrials.gov ID
- NCT07256613
- Acronym / sponsor ID
- KIDPER / 3642/DUHS/Approval/2024/311
- Conditions
- Type 2 Diabetes Mellitus MeSH:D003924, Periodontitis MeSH:D010518, Diabetic Nephropathies MeSH:D003928
- Keywords
- Type 2 Diabetes Mellitus, Uncontrolled Type 2 Diabetes, Diabetes-related nephropathy, Chronic kidney disease (CKD), Diabetic nephropathy, periodontitis, non surgical periodontal therapy, scaling
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 46 participants (actual)
- Lead sponsor
- Dow University of Health SciencesUniversity, hospital or other
- Study start
- 15 May 2025 (actual)
- Primary completion
- 15 May 2026 (actual)
- Study completion
- 19 Aug 2026 (actual)
- First posted
- 1 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Brief Summary (Lay Description)
This research study is being conducted to understand whether treating gum disease (periodontitis) can help improve kidney health in patients who have type-2 diabetes mellitus (T2DM). Both diabetes and gum disease are common long-term conditions that often occur together. People with uncontrolled diabetes are at risk of developing kidney problems due to damage in the small blood vessels of the kidneys - a condition known as diabetic nephropathy.
Scientific evidence has already shown that treating gum disease can help improve blood sugar control in diabetic patients. However, it is still unclear whether gum treatment can also help reduce the risk or severity of kidney-related complications. This study aims to find out if non-surgical periodontal therapy (NSPT), which includes scaling and root planing (deep dental cleaning), has any effect on blood markers of kidney function - specifically urea, creatinine, and estimated glomerular filtration rate (eGFR) - in patients with uncontrolled type-2 diabetes.
The study will be conducted as a randomized controlled trial involving 46 patients with uncontrolled T2DM (HbA1c ≥ 7%) who also have moderate to severe gum disease. Participants will be divided randomly into two groups:
Test Group: Will receive full-mouth non-surgical periodontal therapy (scaling and root planing) and oral hygiene instructions.
Control Group: Will receive oral hygiene instructions only and will get the same gum treatment later (after 90 days, as delayed therapy).
All participants will have their gum health examined, and blood tests will be done at the start and again after 90 days to measure urea, creatinine, and eGFR levels. These tests help determine how well the kidneys are working. The changes in these values before and after gum treatment will show whether improving oral health has any beneficial impact on kidney function in diabetics.
The study is expected to take one year and will be conducted at Dow University of Health Sciences, Karachi. All participants will receive standard dental and laboratory assessments at no cost. The results may help improve future strategies for managing diabetic patients by integrating oral health care with medical care.
Purpose:
To determine whether treating gum disease (through non-surgical periodontal therapy) can improve kidney function markers - urea, creatinine, and eGFR - in patients with uncontrolled type-2 diabetes mellitus.
Question being answered:
Does non-surgical periodontal therapy have a positive effect on kidney function in uncontrolled type-2 diabetic patients by reducing urea and creatinine levels and improving eGFR?
Detailed description
Detailed Description Background and Rationale
Periodontitis and type 2 diabetes mellitus (T2DM) are both chronic, non-communicable diseases with a well-established bidirectional relationship. Individuals with poorly controlled diabetes are at higher risk of developing periodontal inflammation, while untreated periodontitis may contribute to poor glycemic control through systemic inflammation. Among the microvascular complications of diabetes, nephropathy remains a major cause of morbidity and mortality. It is characterized by glomerular damage, resulting in elevated serum creatinine (SCr) and urea levels, and a reduced glomerular filtration rate (GFR).
Although several studies have shown that periodontal therapy can improve glycemic control, there is limited evidence regarding its effects on renal function in diabetic patients. The systemic inflammatory burden caused by chronic periodontitis may exacerbate kidney dysfunction, as inflammatory mediators such as TNF-α, IL-1β, and prostaglandin E2 circulate systemically and contribute to endothelial damage. This study aims to evaluate whether non-surgical periodontal therapy (NSPT), by reducing periodontal inflammation and bacterial load, can positively influence renal biomarkers in patients with uncontrolled type 2 diabetes mellitus.
The study will provide preliminary interventional data on the potential of periodontal therapy as an adjunctive measure in reducing systemic inflammatory load and possibly delaying microvascular complications, such as diabetic nephropathy. This is particularly relevant in the Pakistani population, where both T2DM and periodontitis have high prevalence, yet local interventional evidence remains scarce.
Study Design and Setting
This is a parallel-arm, single-blinded randomized controlled clinical trial designed to evaluate the effect of NSPT on renal function markers in uncontrolled T2DM patients with moderate to severe periodontitis. The study will be conducted at two sites under Dow University of Health Sciences (DUHS), Karachi:
National Institute of Diabetes and Endocrinology (NIDE) - patient screening and medical evaluation.
Dr. Ishrat-ul-Ebad Khan Institute of Oral Health Sciences (DIKIOHS) - periodontal examination and intervention.
The total duration of the study is projected to be 12 months, including patient recruitment, intervention, 3-month follow-up, data analysis, and report preparation.
Sample Size and Allocation
Based on previous studies assessing serum creatinine differences between periodontitis and non-periodontitis groups, a sample size of 23 participants per arm (n=46 total) has been calculated, accounting for 20% attrition. Participants will be randomly assigned to one of two groups using computer-generated random numbers and allocation concealment via Serially Numbered Opaque Sealed Envelopes (SNOSE).
Test Group: Non-surgical periodontal therapy (scaling and root planing) + standardized oral hygiene instructions (OHI).
Control Group: OHI only; scaling and root planing provided after study completion as delayed therapy (DT).
The principal investigator will remain blinded to the intervention assignment during data collection and analysis.
Intervention Details
- Non-Surgical Periodontal Therapy (NSPT) The NSPT intervention includes full-mouth ultrasonic scaling followed by manual root planing using Gracey curettes. This will be performed in a single session by trained and calibrated dental hygienists under supervision. The procedure aims to remove supra- and sub-gingival plaque and calculus, thereby eliminating bacterial niches contributing to inflammation.
- Oral Hygiene Instructions (OHI) All participants will receive standardized instructions based on the Modified Stillman's brushing technique using a soft-bristle toothbrush and fluoridated toothpaste twice daily. Each participant will receive an identical oral hygiene kit to ensure standardization. Compliance will be monitored through self-maintained daily practice sheets reviewed at follow-up visits.
- Delayed Therapy (DT)
Participants in the control arm will receive the same NSPT procedure after completion of the 90-day follow-up period to ensure ethical equivalence.
Clinical and Laboratory Assessments Baseline Examination
At recruitment, each participant will undergo:
Full-mouth periodontal charting (six sites per tooth) for probing depth (PPD), clinical attachment loss (CAL), and bleeding on probing (BOP).
Collection of demographic, medical, and lifestyle data via structured questionnaire.
Blood sampling for baseline measurement of:
Serum creatinine (SCr)
Blood urea nitrogen (BUN)
Glycated hemoglobin (HbA1c)
Estimated glomerular filtration rate (eGFR), calculated using the Modification of Diet in Renal Disease (MDRD) formula.
Follow-Up Examination
At 90 days post-intervention, all parameters will be re-evaluated to assess intra- and inter-group changes in renal and periodontal health indices.
Blood samples will be collected under aseptic conditions by trained personnel and analyzed by the Dow Diagnostic Laboratory using standardized procedures. Serum separation will be done by centrifugation; assays will follow clinical laboratory reference ranges:
SCr normal range: 0.6-1.5 mg/dL
BUN normal range: 30-40 mg/dL
Normal eGFR cutoff: ≥60 mL/min/1.73 m²
Calibration and Quality Control
All periodontal examinations will be performed by the principal investigator (PI), trained and calibrated against a gold standard examiner (the supervisor). Inter- and intra-examiner reliability will be tested before trial initiation using kappa statistics and intra-class correlation coefficients. The two dental hygienists performing the interventions will undergo calibration sessions to standardize SRP procedures. Random 10% re-evaluation of data will be done to ensure consistency.
Data Management and Statistical Analysis
All data will be anonymized using unique participant identifiers. Data entry will be performed using IBM SPSS version 26.0.
Continuous variables will be expressed as mean ± standard deviation, and categorical variables as frequencies and percentages.
Statistical analyses will include:
Wilcoxon signed-rank test: for within-group comparisons (baseline vs. 90-day values).
Mann-Whitney U test: for between-group comparisons.
Correlation analyses: between periodontal parameters (PPD, CAL, BOP) and renal markers (SCr, BUN, eGFR).
Significance level: p ≤ 0.05. Both per-protocol (PPA) and intention-to-treat (ITT) analyses will be performed to ensure robustness of findings.
Ethical Considerations
The study protocol has been reviewed and approved by the Institutional Review Board (IRB) of Dow University of Health Sciences. Written informed consent will be obtained from all participants prior to enrollment, with separate consent forms in English and Urdu to ensure understanding.
Participation is voluntary, and subjects may withdraw at any stage without penalty. All laboratory and dental procedures will be conducted free of cost. Participants in the control group will receive their complete periodontal therapy after the trial. Data confidentiality will be maintained through de-identification and restricted access.
Potential risks include mild discomfort during blood sampling and transient tooth sensitivity following SRP, both of which are minor and self-limiting. No major adverse effects are anticipated. Participants will have access to dental and medical support throughout the study period.
Expected Outcomes
The study anticipates a measurable improvement in renal function biomarkers (reduction in SCr and BUN levels, and improvement in eGFR) among the NSPT group compared to controls after 90 days. This would support the hypothesis that periodontal inflammation contributes to systemic inflammatory load affecting renal physiology.
Findings will help strengthen the understanding of oral-systemic health connections and may encourage multidisciplinary management of diabetic patients involving both dental and medical professionals.
Scientific Significance and Future Implications
This trial will be one of the first interventional studies from Pakistan evaluating the impact of non-surgical periodontal therapy on renal function in uncontrolled diabetics. The results could:
Provide evidence to include periodontal screening as part of diabetes management protocols.
Support collaborative programs between diabetology and dental departments for early detection and management of oral infections.
Encourage larger multicentric clinical trials exploring the long-term effects of periodontal therapy on renal and systemic outcomes in diabetic populations.
The study's integration of oral health and systemic disease management aligns with global efforts to promote interdisciplinary healthcare and may contribute to policy-level recommendations for diabetic patient care.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- Parallel Assignment - Participants are randomly assigned to one of two groups: an intervention group receiving non-surgical periodontal therapy and a control group receiving delayed therapy after the study period.
| Arm | Type | Receives |
|---|---|---|
| Non-Surgical Periodontal Therapy (Scaling and Root Planing + Oral Hygiene Instructions) | Experimental | Procedure: scaling and root planningParticipants in this arm will receive full-mouth non-surgical periodontal therapy, including ultrasonic scaling and manual root planing in a single session performed by trained dental hygienists. This treatment aims to remove supra- and subgingival plaque and calculus to reduce periodontal inflammation. Standardized oral hygiene instructions will also be provided, including demonstration of the Modified Stillman's brushing technique using a soft toothbrush and fluoridated toothpaste twice daily. Participants will be monitored for 90 days to assess changes in renal biomarkers (serum creatinine, blood urea nitrogen, and eGFR) |
| Control - Oral Hygiene Instructions with Delayed Periodontal Therapy | Active comparator | Procedure: scaling and root planningParticipants in the control arm will receive only standardized oral hygiene instructions at baseline and will not undergo scaling and root planing during the 90-day study period. After completion of follow-up assessments, they will receive the same periodontal therapy as the intervention group (delayed therapy) to ensure ethical equivalence |
Who may qualify
- Ages
- 30 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Adults between 30 and 65 years of age
- Men and women previously diagnosed with type 2 diabetes mellitus for at least one year
- Participants with uncontrolled diabetes, defined as HbA1c ≥ 7%
- Presence of moderate to severe gum disease, Stage II or Stage III periodontitis, as determined by dental examination
- Estimated glomerular filtration rate (eGFR) of 60 mL/min/1.73 m² or higher
Key exclusion criteria (10 listed)
- Critically ill individuals or those unable to communicate effectively
- Pregnant or breastfeeding women
- Women currently using hormone replacement therapy or oral contraceptives within the past six months
- Individuals taking steroidal drugs, nonsteroidal anti-inflammatory drugs (NSAIDs), or other anti-inflammatory medications within the past three months, except low-dose aspirin up to 75 mg daily
- Participants with a recent history of major blood loss, trauma, or gastrointestinal bleeding
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| scaling and root planningIntervention 1: Scaling and Root Planing (SRP) + Oral Hygiene Instructions (OHI) Intervention Description: Participants assigned to the intervention arm will receive full-mouth non-surgical periodontal therapy consisting of scaling and root planning (SRP). Ultrasonic scalers will be used to remove supragingival plaque and calculus, followed by hand instruments (curettes and scalers) for subgingival debridement and root planing. The procedure is performed in a single session by trained and calibrated dental hygienists. Participants will also receive standardized oral hygiene instructions (OHI), including demonstration of the Modified Stillman's toothbrushing technique using a soft-bristle toothbrush and fluoridated toothpaste twice daily. Each participant will be provided with an oral hygiene kit to ensure consistency. Postoperative care includes warm saline rinses for three days. No further periodontal treatment will be given during the 90-day follow-up period. | Procedure or surgery | Control - Oral Hygiene Instructions with Delayed Periodontal Therapy, Non-Surgical Periodontal Therapy (Scaling and Root Planing + Oral Hygiene Instructions) |
Primary outcome
Change from Baseline in Serum Creatinine, Blood Urea Nitrogen, and Estimated Glomerular Filtration Rate (eGFR) at 90 Days After Non-Surgical Periodontal Therapy
Time frame: Baseline and 90 days after completion of non-surgical periodontal therapy
The primary outcome will be evaluated by measuring changes in renal function biomarkers, including serum creatinine (mg/dL), blood urea nitrogen (BUN, mg/dL), and estimated glomerular filtration rate (eGFR, mL/min/1.73 m²). These parameters will be assessed at baseline and 90 days post-intervention to determine within- and between-group differences. Serum creatinine and BUN will be analyzed using standard automated laboratory methods, and eGFR will be calculated using the Modification of Diet in Renal Disease (MDRD) equation. A reduction in serum creatinine and BUN levels and an increase in eGFR will indicate improvement in renal function. Data will be statistically analyzed using Wilcoxon signed-rank and Mann-Whitney U tests with a significance threshold of p ≤ 0.05
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Aug 2026.
- Individual participant dataSharing planned: Undecided
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing scaling and root planning in people with Type 2 Diabetes Mellitus MeSH:D003924 and Periodontitis MeSH:D010518, run by Dow University of Health Sciences at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from Baseline in Serum Creatinine, Blood Urea Nitrogen, and Estimated Glomerular Filtration Rate (eGFR) at 90 Days After Non-Surgical Periodontal Therapy (time frame: Baseline and 90 days after completion of non-surgical periodontal therapy). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Aug 2026.